- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06147063
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)
A Phase I, Open-label, Randomized, Active-Controlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 and AZD6563 Vaccine (ARTEMIS-C)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase I, open-label, randomized, active-controlled study to assess the safety and immunogenicity of 2 dosages of AZD9838 and 2 dosages of AZD6563 compared with a licensed SARS-CoV-2 mRNA vaccine in approximately 240 healthy participants. AZD6563 will be assessed in adults 18 years of age and older. AZD9838 will be assessed in adults 18 to 64 years of age only.
The duration of each participant's involvement in the study will be approximately 12 months following administration of study vaccination.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
California
-
Long Beach, California, United States, 90815
- Recruiting
- Research Site
-
Rolling Hills Estates, California, United States, 90274
- Recruiting
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- Recruiting
- Research Site
-
-
Kansas
-
Wichita, Kansas, United States, 67207
- Recruiting
- Research Site
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29405
- Recruiting
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Adults ≥ 18 years at the time of signing informed consent.
- Self-reported History of SARS-CoV-2 infection at least 6 months prior to study vaccination AND/OR prior completion of primary series vaccination against COVID-19, with the final dose received at least 6 months prior to study vaccination
- Negative SARS-CoV-2 RT-PCR test at Visit 1
- Body mass index (BMI) of <35 kg/m2 at screening
- Medically stable - according to the judgement of the investigator, hospitalization within the study is not anticipated and participant is likely to remain in the study through the end of the protocol specified follow-up.
Key Exclusion Criteria:
- Acute illness/infection on day prior or day of dosing
- History of hypersensitivity to any component of the study vaccination, severe adverse reaction associated with a vaccine and/or severe allergic reaction
- Positive COVID-19 test result within 6 months of Visit 1
- Receipt of licensed, authorized, or investigational COVID-19 vaccines in the 6 months prior to administration of study intervention or expected receipt through completion of Visit 5.
- Receipt of any COVID-19 monoclonal antibody (licensed or investigational) within 3 months or receipt of immunoglobulin (non-COVID related) or blood products within 6 months prior to administration of study intervention, or expected receipt during the study
- Receipt of any licensed or investigational vaccine (other than licensed influenza vaccines or non-study COVID-19 vaccines) within 30 days prior to Visit 1 or expected receipt prior to completion of Visit 4. Licensed influenza vaccines are permitted beginning > 14 days before and > 14 days after administration of study intervention.
- Previous history of myocarditis or pericarditis
- Woman who are pregnant, lactating, or of child-bearing potential and not using a contraception or abstinence from at least 4 weeks prior to study vaccination and until at least 6 months after study vaccination
- Lab values above ULN (Serum creatinine, AST, ALT), below LLN (hemoglobin, WBC, Platelet count) or any lab value that in the opinion of the investigator is clinically significant or might confound analysis of the study results. Participants with laboratory values outside of the normal range may have the abnormal test repeated within the screening window and if the values are normal, then the participant can be randomized. If the repeated value remains outside of the normal range but it is not felt to be clinically significant by the Investigator, the case can be discussed with the AstraZeneca study physician and if they both agree the value is not clinically significant, the participant can be randomized
- History of malignancy within 5 years (treated non-melanoma skin cancer and locally treated cervical cancers allowed)
- Known or suspected congenital or acquired immunodeficiency
- Known or suspected autoimmune conditions as determined by history and /or physical examination
- Active infection with hepatitis B or C
- Troponin I levels above the normal range at the screening visit
- History of hypersensitivity to kanamycin or any aminoglycoside antibiotics (eg, neomycin, streptomycin, tobramycin, and gentamicin).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: dosage 1 of AZD9838 18 to 64 years of age
Participants will receive 1 intramuscular dose of AZD9838.
|
Intramuscular (IM) injection.
|
Experimental: Arm 2: dosage 2 of AZD9838 18 to 64 years of age
Participants will receive 1 intramuscular dose of AZD9838.
|
Intramuscular (IM) injection.
|
Active Comparator: Arm 3: licensed mRNA vaccine 18 to 64 years of age
Participants will receive 1 intramuscular dose of the licensed mRNA vaccine.
|
Intramuscular (IM) injection.
|
Experimental: Arm 4: dosage 1 of AZD6563 18 to 64 years of age
Participants will receive 1 intramuscular dose of AZD6563.
|
Intramuscular (IM) injection.
|
Experimental: Arm 5: dosage 2 of AZD6563 18 to 64 years of age
Participants will receive 1 intramuscular dose of AZD6563.
|
Intramuscular (IM) injection.
|
Experimental: Arm 6: dosage 1 of AZD6563 65 years of age and older
Participants will receive 1 intramuscular dose of AZD6563.
|
Intramuscular (IM) injection.
|
Experimental: Arm 7: dosage 2 of AZD6563 65 years of age and older
Participants will receive 1 intramuscular dose of AZD6563.
|
Intramuscular (IM) injection.
|
Active Comparator: Arm 8: licensed mRNA vaccine 65 years of age and older
Participants will receive 1 intramuscular dose of the licensed mRNA vaccine.
|
Intramuscular (IM) injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of immediate unsolicited adverse events (AE)
Time Frame: Within 30 minutes post vaccination
|
Number of participants who experienced immediate unsolicited AEs within 30 minutes post vaccination.
|
Within 30 minutes post vaccination
|
Incidence of solicited adverse reactions (AR)
Time Frame: Through 7 days post vaccination.
|
Number of participants who experienced injection site and systemic solicited ARs through 7 days post vaccination.
|
Through 7 days post vaccination.
|
Incidence of unsolicited adverse events (AE)
Time Frame: Through 28 days post vaccination.
|
Number of participants who experienced unsolicited AEs through 28 days post vaccination.
|
Through 28 days post vaccination.
|
Incidence of serious adverse events (SAE)
Time Frame: Through 12 months post vaccination
|
Number of participants who experienced SAEs through 12 months post vaccination.
|
Through 12 months post vaccination
|
Incidence of medically attended adverse events (MAAE)
Time Frame: Through 12 months post vaccination
|
Number of participants who experienced MAAEs through 12 months post vaccination.
|
Through 12 months post vaccination
|
Incidence of adverse events of special interest (AESI)
Time Frame: Through 12 months post vaccination
|
Number of participants who experience AESIs through 12 months post vaccination.
|
Through 12 months post vaccination
|
Geometric mean titer (GMT) for SARS-CoV-2 ancestral strain neutralizing antibodies
Time Frame: Day 29
|
GMT for SARS-CoV-2 ancestral strain neutralizing antibodies
|
Day 29
|
Geometric mean titer (GMT) for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodies
Time Frame: Day 29
|
GMT for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodies
|
Day 29
|
Geometric mean titer (GMT) for SARS-CoV-2 Omicron XBB.1.5 neutralizing antibodies
Time Frame: Day 29
|
GMT for SARS-CoV-2 Omicron XBB.1.5
neutralizing antibodies
|
Day 29
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 ancestral strain neutralizing antibodies
Time Frame: Day 1 to Day 29
|
GMFR for SARS-CoV-2 ancestral strain neutralizing antibodies
|
Day 1 to Day 29
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodies
Time Frame: Day 1 to Day 29
|
GMFR for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodies
|
Day 1 to Day 29
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 Omicron XBB.1.5 neutralizing antibodies
Time Frame: Day 1 to Day 29
|
GMFR for SARS-CoV-2 Omicron XBB.1.5
neutralizing antibodies
|
Day 1 to Day 29
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 ancestral strain
Time Frame: Day 1 to Day 29
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 ancestral strain, defined as GMFR >=4 from baseline
|
Day 1 to Day 29
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron BA.4/5
Time Frame: Day 1 to Day 29
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron BA.4/5, defined as GMFR >=4 from baseline
|
Day 1 to Day 29
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron XBB.1.5
Time Frame: Day 1 to Day 29
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron XBB.1.5,
defined as GMFR >=4 from baseline
|
Day 1 to Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric mean titer (GMT) for SARS-CoV-2 ancestral strain neutralizing antibodies
Time Frame: Day 1 to Day 360
|
GMT for SARS-CoV-2 ancestral strain neutralizing antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean titer (GMT) for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodies
Time Frame: Day 1 to Day 360
|
GMT for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean titer (GMT) for SARS-CoV-2 Omicron XBB.1.5 neutralizing antibodies
Time Frame: Day 1 to Day 360
|
GMT for SARS-CoV-2 Omicron XBB.1.5
neutralizing antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 ancestral strain neutralizing antibodies
Time Frame: Day 1 to Day 360
|
GMFR for SARS-CoV-2 ancestral strain neutralizing antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodies
Time Frame: Day 1 to Day 360
|
GMFR for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 Omicron XBB.1.5 neutralizing antibodies
Time Frame: Day 1 to Day 360
|
GMFR for SARS-CoV-2 Omicron XBB.1.5
neutralizing antibodies by visit.
|
Day 1 to Day 360
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 ancestral strain
Time Frame: Day 1 to Day 360
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 ancestral strain, defined as GMFR >=4 from baseline by visit.
|
Day 1 to Day 360
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron BA.4/5
Time Frame: Day 1 to Day 360
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron BA.4/5, defined as GMFR >=4 from baseline by visit.
|
Day 1 to Day 360
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron XBB.1.5
Time Frame: Day 1 to Day 360
|
Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron XBB.1.5,
defined as GMFR >=4 from baseline by visit.
|
Day 1 to Day 360
|
Geometric mean titer (GMT) for SARS-CoV-2 ancestral strain S protein binding antibodies
Time Frame: Day 1 to Day 360
|
GMT for SARS-CoV-2 ancestral strain S protein binding antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean titer (GMT) for SARS-CoV-2 Beta variant S protein binding antibodies
Time Frame: Day 1 to Day 360
|
GMT for SARS-CoV-2 Beta variant S protein binding antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean titer (GMT) for SARS-CoV-2 Delta variant S protein binding antibodies
Time Frame: Day 1 to Day 360
|
GMT for SARS-CoV-2 Delta variant S protein binding antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean titer (GMT) for SARS-CoV-2 Omicron subvariant S protein binding antibodies
Time Frame: Day 1 to Day 360
|
GMT for SARS-CoV-2 Omicron subvariant S protein binding antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 ancestral strain S protein binding antibodies
Time Frame: Day 1 to Day 360
|
GMFR for SARS-CoV-2 ancestral strain S protein binding antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 Beta variant S protein binding antibodies
Time Frame: Day 1 to Day 360
|
GMFR for SARS-CoV-2 Beta variant S protein binding antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 Delta variant S protein binding antibodies
Time Frame: Day 1 to Day 360
|
GMFR for SARS-CoV-2 Delta variant S protein binding antibodies by visit.
|
Day 1 to Day 360
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 Omicron subvariant S protein binding antibodies
Time Frame: Day 1 to Day 360
|
GMFR for SARS-CoV-2 Omicron subvariant S protein binding antibodies by visit.
|
Day 1 to Day 360
|
Proportion of participants with S protein binding antibody seroresponse against SARS-CoV-2 ancestral strain
Time Frame: Day 1 to Day 360
|
Proportion of participants with S protein binding antibody seroresponse against SARS-CoV-2 ancestral strain by visit.
|
Day 1 to Day 360
|
Proportion of participants with S protein binding antibody seroresponse against SARS-CoV-2 Beta variant
Time Frame: Day 1 to Day 360
|
Proportion of participants with S protein binding antibody seroresponse against SARS-CoV-2 Beta variant by visit.
|
Day 1 to Day 360
|
Proportion of participants with S protein binding antibody seroresponse against SARS-CoV-2 Delta variant
Time Frame: Day 1 to Day 360
|
Proportion of participants with S protein binding antibody seroresponse against SARS-CoV-2 Delta variant by visit.
|
Day 1 to Day 360
|
Proportion of participants with S protein binding antibody seroresponse against SARS-CoV-2 Omicron subvariant
Time Frame: Day 1 to Day 360
|
Proportion of participants with S protein binding antibody seroresponse against SARS-CoV-2 Omicron subvariant by visit.
|
Day 1 to Day 360
|
Geometric mean response of S-specific Th1 and Th2 by cytokine-producing T cells by phenotype
Time Frame: Day 1 to Day 180
|
Geometric mean response of S-specific Th1 and Th2 by cytokine-producing T cells by phenotype as measured by an intracellular cytokine staining assay over time.
|
Day 1 to Day 180
|
Incidence and titer of H. pylori and human anti-ferritin antibodies
Time Frame: Day 1 to Day 360
|
Incidence and titer of H. pylori and human anti-ferritin antibodies over time.
|
Day 1 to Day 360
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D8670C00001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States